To further validate that the synergistic anti-tumor effect of TGF-β blockade and anti-PD-1 combination therapy was directly dependent on CD8+ T cells, CD8+ T cells were depleted in vivo by the anti-mouse CD8α antibody. This evidence concerns the gene PDCD1 and neoplasm.